Search details
1.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(8): 995-1008, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35798016
2.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Lancet Gastroenterol Hepatol
; 9(4): 310-322, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38364832
3.
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Cancer Med
; 12(22): 20847-20863, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37935428
Results
1 -
3
de 3
1
Next >
>>